S., Gelino, C., Stephens, D., Lunine, J
Both culture and in vivo work have shown that metformin treatment can reduce p-Ser129 -synuclein either by epigenetic regulator enhancer of zeste homolog 2-mediated proteasomal degradation or by inhibition of the mTOR to activate protein phosphatase 2A (PP2A) in both AMPK-dependent and AMPK-independent manners ( Figure 1
Research on GLP-1 medications is still evolving, and we expect to have much more information in the next few years
[19] Fragile X syndrome: A 2015 Cochrane review of ALCAR in fragile X syndrome found only two placebo-controlled trials, each of low quality, and concluded that ALCAR is unlikely to improve intellectual functioning or hyperactive behavior in children with this condition
Athletes and gym-goers find they can train harder, for longer, without feeling depleted